Chemical Optimization Designed to Increase the in vivo Efficacy of HM-27 for the

旨在提高 HM-27 体内功效的化学优化

基本信息

批准号：
8395611
负责人：
Lori A Hazlehurst
金额：
$ 15.62万
依托单位：
MODULATION THERAPEUTICS, INC.
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-09-01 至 2013-08-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8395611
关键词：
Affinity Amino Acid Sequence Antibodies Antineoplastic Agents Apoptotic Binding Biological Assay Biological Availability Biological Markers Biotin Bone Diseases Bone Marrow Businesses CD44 gene Cancer Center Cell Death Cell Line Cell membrane Cells Characteristics Chemicals Clinical Clinical Data Clinical Research Clinical Trials Collaborations Collecting Cell Data Development Doctor of Pharmacy Dose Drug Kinetics Employee Extracellular Domain FDA approved Fibronectins Funding Goals Grant Half-Life Hematologic Neoplasms Hematopoietic Home environment Homing Human Immune Implant In Vitro Inhibitory Concentration 50 Label Laboratories Lead Length Licensing MSX1 gene Malignant - descriptor Malignant Neoplasms Measurement Measures Mediation Melphalan Modeling Multiple Myeloma Mus Necrosis Normal Cell Pathway interactions Patients Peptide Hydrolases Peptide Sequence Determination Peptides Pharmaceutical Preparations Pharmacodynamics Pharmacologic Substance Phase Phase I Clinical Trials Reagent Recombinants Relapse Request for Applications Research Personnel Resistance Route Safety Site Solid Neoplasm Surface Surface Plasmon Resonance Technology Testing Therapeutic Therapeutic Uses Toxic effect Variant analog arm cell killing cell stroma clinical efficacy commercialization design drug candidate improved in vitro Assay in vivo killings loris novel peptide analog peptidomimetics pre-clinical protein protein interaction scaffold small molecule tumor tumor growth

项目摘要

DESCRIPTION (provided by applicant): This application requests funds to aid in obtaining the necessary additional preclinical data needed for commercialization of a promising new and novel drug candidate for the treatment of multiple myeloma. A small business, Modulation Therapeutics Incorporated, has licensed this technology from the Moffitt Cancer Center and its employee, Dr. Priyesh Jain, in collaboration with Dr. Mark McLaughlin and Dr. Lori Hazlehurst at Moffitt Cancer Center and aided by co-investigator Richard Lush, PharmD, are proposing to synthesize analogs expected to have better bioavailability and that improve or maintain direct binding affinities for CD44 and in vitro IC50 activity. We will measure preliminary PK studies, and confirmatory in vitro and in vivo 5TGM1 MM tumor growth inhibition studies in Phase 1 of the grant. PUBLIC HEALTH RELEVANCE: This application requests funds to aid a new small business, Modulation Therapeutics Incorporated, in obtaining the necessary additional pre-clinical data needed for commercialization of a promising new and novel drug candidate for the treatment of multiple myeloma. The new drug candidate kills human multiple myeloma tumors, the second most common hematological malignancy in humans, in immune-compromised mice implanted with the human tumor at does that show no obvious toxicity to the mice.

描述（由申请人提供）：本申请要求资金有助于获得有希望的新药物候选多发性骨髓瘤所需的必要的临床前数据。一家小型企业，调节治疗剂纳入了莫菲特癌症中心及其员工Priyesh Jain博士的许可和体外IC50活性。我们将在赠款的第1阶段中衡量初步的PK研究，并在体外和体外和体内5TGM1 MM肿瘤生长抑制研究。公共卫生相关性：本申请要求资金帮助新的小型企业，调制治疗剂，以获取商业化所需的必要的临床前数据，以构成多个骨髓瘤治疗的有希望的新型和新型药物候选者。新药候选者杀死了人类多发性骨髓瘤肿瘤，这是人类中第二大最常见的血液系统恶性肿瘤，在植入人类肿瘤的免疫功能低下的小鼠中，对小鼠没有明显的毒性。